All articles tagged with #ecnoglutide
A new drug called ecnoglutide shows promise as a treatment for type 2 diabetes and weight loss, potentially rivaling Ozempic, with clinical trials indicating it may be more effective in lowering blood sugar and promoting weight loss than dulaglutide, and similar or better than semaglutide, though it is not yet approved for market.
A phase 3 trial shows that ecnoglutide, a once-weekly injection for type 2 diabetes, is as effective as dulaglutide in lowering blood sugar and may lead to greater weight loss, with potential benefits for diabetes management and heart health, and is easier to produce.
Ecnoglutide, a new GLP-1 receptor agonist, demonstrated significant weight loss and improved cardiometabolic risk factors in a phase 3 trial involving overweight and obese adults, showing promise as a personalized obesity therapy with potential advantages over existing treatments.
Hangzhou Sciwind Biosciences has developed ecnoglutide, a promising obesity drug that showed over 15% weight loss in late-stage trials, positioning it as a competitor to Eli Lilly's Zepbound and Novo Nordisk's Wegovy, with potential approval in China by 2026 and plans for international development.